A COST-UTILITY ANALYSIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND IRON DEFICIENCY ANEMIA IN THE NETHERLANDS: REDUCED HYPOPHOSPHATEMIA AND FRACTURE INCIDENCE WITH FERRIC DERISOMALTOSE VERSUS FERRIC

被引：0
|
作者：
Oron, U. [1 ]
Koek, G. [2 ]
Fijn, R. [3 ]
Pollock, R. [4 ]
机构：
[1] C3 Consultancy Cooperat, Egmond Aan Zee, Netherlands
[2] Maastricht Univ, Med Ctr, Maastricht, Limburg, Netherlands
[3] Alrijne Healthcare Grp, Leiden, South Holland, Netherlands
[4] Covalence Res Ltd, Harpenden, Herts, England
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE314
引用
收藏
页码：S116 / S116
页数：1
相关论文
共 50 条
  • [31] Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
    Aksan, Ayseguel
    Dignass, Axel
    Stein, Juergen
    ADVANCES IN THERAPY, 2019, 36 (08) : 1817 - 1820
  • [32] Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
    Richard F. Pollock
    Gorden Muduma
    Advances in Therapy, 2019, 36 : 1821 - 1825
  • [33] Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea
    Eun-A Lim
    Hyun-Soon Sohn
    Haeyoung Lee
    Sang-Eun Choi
    Cost Effectiveness and Resource Allocation, 12
  • [34] Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea
    Lim, Eun-A
    Sohn, Hyun-Soon
    Lee, Haeyoung
    Choi, Sang-Eun
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2014, 12
  • [35] FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease
    Evstatiev, Rayko
    Marteau, Philippe
    Iqbal, Tariq
    Khalif, Igor L.
    Stein, Juergen
    Bokemeyer, Bernd
    Chopey, Ivan V.
    Gutzwiller, Florian S.
    Riopel, Lise
    Gasche, Christoph
    GASTROENTEROLOGY, 2011, 141 (03) : 846 - U558
  • [36] Efficacy and safety of a restrictive ferric carboxymaltose infusion strategy for iron deficiency anemia in inflammatory bowel disease patients
    Crispino, F.
    Grova, M.
    Maida, M.
    Renna, S.
    Casa, A.
    Rizzo, G.
    Macaluso, F. S.
    Orlando, A.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S292 - S292
  • [37] Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with iron isomaltoside or ferric carboxymaltose: results of a prospective cluster randomised cohort study
    Detlie, T. E.
    Lindstrom, J. C.
    Jahnsen, M. E.
    Finnes, E.
    Zoller, H.
    Moum, B.
    Jahnsen, J.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S482 - S483
  • [38] IV IRON TREATMENT OF IRON DEFICIENCY ANEMIA WITH FERUMOXYTOL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE UNABLE TO TAKE ORAL IRON: A RANDOMIZED CONTROLLED TRIAL VERSUS FERRIC CARBOXYMALTOSE
    Strauss, William
    Dahl, Naomi V.
    Jiang, John
    GASTROENTEROLOGY, 2019, 156 (06) : S1107 - S1108
  • [39] Efficacy and Cost Effectiveness of Intravenous Ferric Carboxymaltose Versus Iron Sucrose in Adult Patients with Iron Deficiency Anemia
    Basha, Ahmed
    Izham, Mohamed
    Hamad, Anas
    Chandra, Prem
    Omar, Nabil E.
    Abdulla, Mohammad Abdul-Jaber
    Aldapt, Mahmood B.
    Hussein, Radwa M.
    Mahfouz, Ahmed
    Adel, Ahmed A.
    Shwaylia, Hawraa M.
    Ekeibed, Yeslem Mohamed Aly
    AbuMousa, Rami
    Yassin, Mohamed A.
    BLOOD, 2020, 136
  • [40] Iron deficiency anaemia and quality of life in Inflammatory Bowel Disease: Prospective cohort study of ferric derisomaltose on quality of life and work productivity in patients with IBD
    Goodhand, J. R.
    Parkinson, M.
    Bewshea, C.
    Ahmad, T.
    Kennedy, N. A.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1124 - +
12345